Evotec Presents the Paradigm Shift in Biologics at Capital Markets Day



HAMBURG, GERMANY/ACCESSWIRE/November 2, 2022/ Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today provides an update on its Capital Markets Day on how the company is taking significant steps to transform the manufacture of biologics to enable global access.

The program entitled: “Paradigm shift in Biologics” will take place at its J.POD ® Redmond, WA (USA) facility. In line with the theme, capital market players and thought leaders will learn how Evotec’s subsidiary, Just – Evotec Biologics, is making significant progress in transforming biologics manufacturing to expand global access to biologics. quality biotherapeutic products in support of Evotec’s mission: “Together for medicines that matter”.

The Capital Markets Day agenda will include a tour of the state-of-the-art cGMP biofabrication facility of Just – Evotec Biologics (J.POD ® ) and presentations highlighting how the company uses its highly integrated AI/ML-based platforms in discovery, process development and continuous manufacturing. Overall, attendees will fully understand how the company’s expertise and innovative technology will disrupt today’s biologics manufacturing market.

Dr. Werner Lanthaler, Managing Director of Evotec, said: “The biologics manufacturing industry is steeped in decades-old technology, which has impeded global access to important biotherapeutics. Right – Evotec Biologics’ technology platforms unlock the potential of biologics for diseases affecting large and small patient populations and enable affordable commercialization strategies for effective new drugs and combination antibody therapies. That’s what we mean by: Together for the drugs that matter.”

Dr. Linda Zuckerman, EVP and Global Head of Biotherapeutics, said: “We are well ahead of the curve and implementing our continued manufacturing for biotherapeutics. Combined with our AI/ML-based discovery and design capabilities, we are well positioned to fulfill our mission of expanding global access to biotherapeutics.

Just – Evotec Biologics, recently joined the U.S. Department of Defense (“DOD”) Advanced Development and Manufacturing Facility Network, following an extensive vetting process that led to a one-year contract. worth up to $49.9 million for the rapid development of monoclonal antibodies based on prototype pharmaceutical antibodies.

Just – Evotec Biologics announced today that it has been shortlisted for a second award in the Accelerated Antibodies program.

The company recently inaugurated a second biopharmaceutical manufacturing facility, J.POD ® Toulouse, France (EU), at the Curie Campus of Evotec. Clone of the Redmond factory, the Toulouse J.POD ® will bring advanced biomanufacturing to the EU.

Dr. John Erickson, a veteran industry leader, said: “There is a growing consensus in the industry that biopharmaceutical factories need to be smaller and more flexible. These goals are synergistic and I believe that integrated and continuous bioprocessing is a key enabler for both.

About Capital Markets Day
Evotec is hosting its Capital Markets Day on November 2, 2022, starting at 9:00 a.m. PDT (12:00 p.m. EDT, 5:00 p.m. CET) with a site visit. The meeting will take place on-site at Just – Evotec Biologics’ Redmond Facility, J.POD ® Redmond, WA (USA). The presentation will be broadcast live webcast beginning at 11:00 a.m. PDT (2:00 p.m. EDT, 7:00 p.m. CET) and a recording will be available at www.evotec.com the next day.

About Dr. John Erickson
The son of a NASA engineer, Dr. Erickson has always had a natural curiosity and a passion for innovation. Dr. Erickson holds a BA in Biology and Chemistry from Amherst College and a Masters in Chemical Engineering Practice and Ph.D. in Chemical Engineering from MIT. He first worked in industrial enzymology at Rhône-Poulenc before joining the biopharmaceutical industry. After joining GSK, he held various positions in process development, project management and manufacturing for 29 years. One of the highlights of this period was working with other industry colleagues on the A-mAb case study. Most recently, Dr. Erickson served as Vice President, Biopharmaceutical and Sterile Manufacturing Science and Technology, where he was responsible for scientific oversight and support for commercial biopharmaceutical drug substance and sterile filling/finishing of biopharmaceuticals. and small molecules.

Dr. Erickson started a consulting company in 2019. He has been a consultant for the National Institute for Innovation in Biopharmaceutical Manufacturing (“NIIMBL”), a public/private partnership, since 2019 as a Senior Fellow and has been Acting Chief Technology Officer since 2020. At NIIMBL, he applies his perspective and extensive industry experience to ensure that NIIMBL’s investments are aligned with current industry needs; support the management of a portfolio of impactful projects; and help lead technology initiatives and projects that will benefit the biopharmaceutical manufacturing ecosystem.

Just – Evotec Biologics, 100% owned by Evotec SE, is a leading biologics platform company that leverages AI/ML technologies and advanced molecular design, cell line development, scale-up of ongoing manufacturing processes and strategies to advance biotherapy from discovery to clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in data science, protein, process and manufacturing, including automation, with highly integrated and flexible capabilities to break through barriers scientific and economic aspects associated with the development of therapeutic proteins. Our goal is to accelerate and expand access to biotherapies through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more about www.just-evotecbiologics.com .

Evotec is a life sciences company with a unique business model that pursues its mission to discover and develop highly effective treatments and bring them to patients. The Company’s multi-modality platform includes a unique combination of innovative technology, data and science for the discovery, development and production of first-class, first-class pharmaceuticals. Evotec leverages this “data-driven R&D highway to cure” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotech companies, academic institutions, as well as other health actors. Evotec has strategic activities in a wide range of currently underserved therapeutic areas, including neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world’s first pipeline of innovative co-owned therapeutics and has to date established a portfolio of over 200 proprietary and co-owned R&D projects, from early discovery to clinical development. Evotec operates worldwide with over 4,500 highly skilled people. The Company’s 16 sites offer highly synergistic technologies and services and function as complementary centers of excellence. For more information, visit www.evotec.com and follow us on Twitter @Evotec and LinkedIn .

This announcement contains forward-looking statements regarding future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “could”, “plan”, “potential”, “should”, “target”, ” ” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements include comments regarding Evotec’s expectations for revenue, group EBITDA and non-partnership R&D expenditure. These forward-looking statements are based on currently available information and on expectations and assumptions that Evotec believed were reasonable at the time such statements were made. No assurance can be given that these expectations will prove to be correct. These statements involve known and unknown risks and are based on a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec’s control. Evotec expressly disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances about which any statement is based.

Evotec SE media contact:
Gabriele Hansen, SVP Head of Global Corporate Communications, Phone: +49.(0)40.56081-255, [email protected]

Hinnerk Rohwedder, Senior Specialist Corporate Communications, Tel. : +49.(0)151 4070-4843, [email protected]

Evotec SE IR contact:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, [email protected]


See the source version on accesswire.com: